DSpace Repository

Treatment of Crohn¿s-Related Rectovaginal Fistula With Allogeneic Expanded-Adipose Derived Stem Cells: A Phase I¿IIa Clinical Trial

Show simple item record

APA

García-Arranz, M. & Herreros, M.D. & Gonzalez-Gómez, Carolina & De-La-Quintana, Paloma & Guadalajara, H. & Georgiev-Hristov, Tihomir & Trébol, Jacobo & García-Olmo, Damian (2016 ) .Treatment of Crohn¿s-Related Rectovaginal Fistula With Allogeneic Expanded-Adipose Derived Stem Cells: A Phase I¿IIa Clinical Trial.

ISO 690

García-Arranz, M. & Herreros, M.D. & Gonzalez-Gómez, Carolina & De-La-Quintana, Paloma & Guadalajara, H. & Georgiev-Hristov, Tihomir & Trébol, Jacobo & García-Olmo, Damian. 2016 .Treatment of Crohn¿s-Related Rectovaginal Fistula With Allogeneic Expanded-Adipose Derived Stem Cells: A Phase I¿IIa Clinical Trial.

https://hdl.handle.net/20.500.12080/39679
dc.contributor.author García-Arranz, M.
dc.contributor.author Herreros, M.D.
dc.contributor.author Gonzalez-Gómez, Carolina
dc.contributor.author De-La-Quintana, Paloma
dc.contributor.author Guadalajara, H.
dc.contributor.author Georgiev-Hristov, Tihomir
dc.contributor.author Trébol, Jacobo
dc.contributor.author García-Olmo, Damian
dc.date.accessioned 2024-02-10T19:28:21Z
dc.date.available 2024-02-10T19:28:21Z
dc.date.created 2016
dc.date.issued 2016
dc.identifier.uri https://hdl.handle.net/20.500.12080/39679
dc.description.abstract The aim of this clinical trial was to determine the safety and feasibility of expanded allogeneic adiposederived stem cells to treat Crohn¿s-related rectovaginal fistula (CRRVF). We designed a phase I¿II clinical trial (https://ClinicalTrials.gov,NCT00999115)to treat10patientswithCRRVF.Patients receivingbiological therapy during follow-upwere excluded. Curettage was performed, and a vaginal or rectal flap was added if the surgeon considered it necessary. The therapeutic protocol included intralesional injection of 20million stem cells in the vaginal walls (submucosal area) and fistula tract. Healing was evaluated 12 weeks later. If the fistula had not healed, a second dose of 40million stem cells was administered. Patient follow-up was 52weeks from last cell injection. Healingwas defined as re-epithelialization of both vaginal and rectal sides and absence of vaginal drainage. Cytokines and immunological blood testsweremonitored. Serious adverse events or rejection issues were not observed. Five patients were excluded because biologicdrugs wererequired totreat a Crohn¿s disease flare-up during follow-up. Cytokine profiles andimmunotoxicity assays showed no statistically significant alterations. Sixty percent of the nonexcluded patients achievedacompletehealing.Expandedallogeneicadipose-derivedstem-cell injection isasafeandfeasible therapy for treating CRRVF, and the healing success rate seems promising (60%). The results of this trial encourage further exploration into this therapy. es_ES
dc.format application/pdf es_ES
dc.language eng es_ES
dc.rights CC-BY es_ES
dc.rights.uri http://creativecommons.org/licenses/by/4.0/deed.es es_ES
dc.source STEMCELLS TRANSLATIONALMEDICINE es_ES
dc.title Treatment of Crohn¿s-Related Rectovaginal Fistula With Allogeneic Expanded-Adipose Derived Stem Cells: A Phase I¿IIa Clinical Trial es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.rights.accessrights info:eu-repo/semantics/openAccess es_ES
dc.identifier.location N/A es_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

CC-BY Except where otherwise noted, this item's license is described as CC-BY

Search DSpace


Browse

My Account

Social Media